含三种抗逆转录病毒药物的新型注射用纳米粒组合首次人体试验
TLC-ART 101是一种含洛匹那韦、利托那韦和替诺福韦的注射用药物组合纳米粒(DcNP)。这项首次人体试验在12名无HIV感染者中评估单次皮下注射的安全性及药代动力学。结果显示洛匹那韦半衰期达17天且可检测至两个月,但全身超敏反应常见,需进一步机制研究。
要点
- 最高剂量组洛匹那韦中位半衰期17天,多数参与者可检测至两个月。
- 替诺福韦血浆半衰期3.5天,细胞内替诺福韦二磷酸检测至14天。
- 利托那韦半衰期仅12小时,未见有意义的延长。
核心结论
- 该DcNP首次人体应用可使洛匹那韦检测至两个月、替诺福韦血浆检测至四天,利托那韦未见有意义延长。
- 全身超敏反应常见,虽未观察到IgE升高,但需进一步机制理解后方可继续开发该DcNP管线。
研究设计与样本
- 首次人体、适应性试验,三个剂量队列(1.5、3.0、4.0 mL)单次皮下给药,观察至64天。
- 纳入12名无HIV感染者,全部完成研究;在血浆、外周血单核细胞(PBMC)和淋巴结(n=2)中检测药物浓度。
主要发现
- 最高剂量组洛匹那韦中位T1/2为17天,多数参与者可检测至两个月。
- 利托那韦T1/2为12小时;替诺福韦血浆T1/2为3.5天,替诺福韦二磷酸在细胞内检测至14天。
- 三种药物的总暴露(AUC)在PBMC中均高于血浆。
- 1名参与者发生过敏反应,4名出现非严重超敏事件(皮疹、唇肿胀、全身瘙痒)。
- 所有参与者均出现1-2级注射部位反应。
临床怎么用
- 该制剂尚处早期研究阶段,超敏反应常见,暂不支持临床常规使用。
- 洛匹那韦长效特征明显,但利托那韦未延长,需优化组合配方。
局限性
- 样本量小(12人),淋巴结检测仅2例。
- 仅在无HIV感染者中单次给药,未评估多次给药及患者群体。
- 超敏反应机制未明,未观察到IgE升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-acting antiretroviral therapy may improve adherence and decrease stigma, yet affordable combination formulations for global usage are lacking. The TLC-ART program engineered an injectable 3-drug combination in a novel nanoparticle (DcNP) product "TLC-ART 101," composed of lopinavir (LPV), ritonavir (RTV), and tenofovir (TVF) and two lipid excipients. We report safety and pharmacokinetics from this first-in-human study. METHODS: Three dose cohorts of people without HIV received a single subcutaneous dose of 1.5, 3.0 or 4.0 mL in an adaptive trial of up to64 days. LPV, RTV, and TFV were measured over time in plasma, peripheral blood mononuclear cells (PBMC), and lymph nodes (n=2). RESULTS: All 12 participants completed the study. One participant experienced anaphylaxis, and four had non-serious hypersensitivity events (rash, lip swelling, generalized pruritis). All participants had grade 1-2 injection-site reactions.. At the highest dose, median LPV T1/2 was 17 days, and LPV was detectable through two months in most participants. RTV T1/2 was 12hrs. Plasma TFV T1/2 was 3.5 days; TFV-diphosphate was detected intracellularly through 14 days. Total exposure (AUC) was higher in peripheral blood mononuclear cells versus plasma for all 3 drugs. CONCLUSIONS: The first human application of this novel HIV DcNP resulted in detection of LPV through two months and TFV up to four days in plasma, and no meaningful prolongation of RTV. Systemic hypersensitivity was common, and although IgE elevation was not observed, additional mechanistic understanding is required prior to further development of this DcNP pipeline.
引用
- Bender Ignacio RA, Jonsson C, Perazzolo S, et al. A novel injectable drug-combination nanoparticle containing three antiretrovirals designed for HIV treatment: A first-in-human trial. J Infect Dis. 2026. PMID: 42925035. doi:10.1093/infdis/jiag504
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。